PregnancyNCT01661348
The Use of the Prevena Incision Management System to Reduce Post-operative Cesarean Delivery Wound Complications
An observational study of Pregnancy, run by University of Oklahoma at 1 site in United States.
Trial summary
Aim 1: Assess the effectiveness of the Prevena Incision Management System in decreasing postoperative surgical site infections in the obese parturient undergoing non-emergent cesarean delivery. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Pregnancy
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2012to Jul 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Study population: All eligible patients will be approached for consent to participate in the study prior to surgical procedure.
Who may be able to join
- Women greater than or equal to 18-years-of-age having a non-emergent Cesarean delivery, primary or repeat procedure, without evidence of active infection at the time of the procedure
- Patient with BMI ≥ 30 kg/m2 at the time of hospital admission
- Patient able to provide informed consent for study
- Patient able to complete follow-up
Who cannot join
- Males
- Females under the age of 18
- Known sensitivity to silver due to the presence of silver in the skin interface layer of the Prevena
- Patients unable to consent
- Patients in active labor
- Patients with a diagnosis of preterm premature rupture of membranes
- Patients with known or suspected infection at the time of Cesarean delivery
- Patients with a contraindication to use of the Prevena Incision Management System
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
About this study
Official title: Reduction of Post Operative Wound Complications in Patients Undergoing Cesarean Delivery With the Use of the Prevena Incision Management System
Aim 1: Assess the effectiveness of the Prevena Incision Management System in decreasing postoperative surgical site infections in the obese parturient undergoing non-emergent cesarean delivery.
Aim 2: Assess patient satisfaction after using the Prevena Incision Management System following a non-emergent cesarean delivery.
Our overall long term goal is to reduce morbidity and incidence of surgical site infection (SSI) in obese parturient who undergo non-emergent cesarean delivery.
Read the detailed description
In the United States, the cesarean delivery rate continues to rise. In 2007, approximately 32% of all births occurred by Cesarean delivery, translating to 1.4 million women who underwent this operative procedure. Oklahoma is on par with the national average, with 33.6 % of births occuring by Cesarean delivery (1). Although in 2006 Cesarean delivery was the most commonly performed surgical procedure in the United States, it remains vulnerable to common, as well as rare, complications. Despite continued advances in surgical and aseptic technique, surgical site infections (SSI) continue to be an area of concern for patients, physicians, hospitals, and insurers.
In addition to their negative impact on patient quality of life, surgical site infections (SSI) have been estimated to require an additional three thousand dollars per infection in healthcare expenditure (2). In the surgical patient, it has been estimated that SSI account for 25 to 38% of hospital acquired infections (3-4) and 2-5% of patients undergoing surgery of any type will develop a SSI (5). In cesarean delivery in particular, rates of SSI are between 3 to 15%, depending on the population, definition of SSI, and modifiable risk factors (6). In particular, one factor shown to increase risk of SSI in multiple studies is obesity with odds ratios 1.1-4.79 depending on degree of BMI stratification (6-8). Given its prevalence and cost, SSI represents a postoperative complication with far reaching consequences and making it an area of increasing focus for research.
Recently, negative pressure wound therapy has come to the forefront in demonstrating improved healing and reduced complications in open and closed surgical wounds of various types. A review of the literature illustrates that prophylactic negative pressure wound therapy device effectiveness in reducing SSI has not been widely evaluated in cesarean deliveries. The goal of this study is to evaluate wound infection rates with the use of the Prevena Incision Management System in obese patients undergoing non-emergent cesarean delivery at a tertiary care center. We propose to initiate a randomized clinical trial of the Prevena Incision Management System in a novel population of patients at high risk of surgical site infection. Given the possibility of unexpected challenges, we propose to begin this project with a pilot study in order to help elucidate factors that may need to be including in a larger study in the future. Also, we anticipate that the pilot study will give us a better insight into the rates of wound complications and potential difference between groups in order to better power a larger study.
Rationale for study: Obese patients undergoing Cesarean deliveries have frequent SSIs secondary to modifiable and non-modifiable risk factors. A randomized controlled trial of Prevena Incision Management System, a single use negative pressure therapy unit designed for placement over clean closed surgical incisions, will help reduce rates of surgical site infections and increase the overall quality of life of our patients.
- Conditions
- Pregnancy
- Keywords
- Cesarian section, Pregnancy, Incision management
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Prevena System placement | Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group). | |
| Standard of care postoperative care | Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of Wound Infections
Measured: The percent of patients with wound infections will be summarized at the 5-7 day post-operative assessment, the 14-21 day post-operative assessment, and the 6-week follow-up visit. The rate of wound infections will be evaluated at each time point.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2012 (estimated)
- Study startJul 2012
- Primary completionJul 2014 (estimated)
- Study completionJul 2014 (estimated)
Why it stopped: Did not receive funding.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PregnancyStudies of the same condition, open and under way.
- More trials run by University of OklahomaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oklahoma
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Katherine M Smith, MD, Principal investigator, University of OklahomaElise Eckhardt, MD, Principal investigator, University of Oklahoma
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01661348
- Sponsor's protocol ID
- Prevena-Smith
- Status last verified
- Oct 2013
- First submitted
- 26 Jul 2012
- Last updated
- 16 Oct 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reduction of Post Operative Wound Complications in Patients Undergoing Cesarean Delivery With the Use of the Prevena Incision Management System
- ClinicalTrials.gov ID
- NCT01661348
- Acronym / sponsor ID
- Prevena-Smith
- Conditions
- Pregnancy
- Keywords
- Cesarian section, Pregnancy, Incision management
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Did not receive funding.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of OklahomaUniversity, hospital or other
- Study start
- Jul 2012
- Primary completion
- Jul 2014 (estimated)
- Study completion
- Jul 2014 (estimated)
- First posted
- 9 Aug 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim 1: Assess the effectiveness of the Prevena Incision Management System in decreasing postoperative surgical site infections in the obese parturient undergoing non-emergent cesarean delivery.
Aim 2: Assess patient satisfaction after using the Prevena Incision Management System following a non-emergent cesarean delivery.
Our overall long term goal is to reduce morbidity and incidence of surgical site infection (SSI) in obese parturient who undergo non-emergent cesarean delivery.
Detailed description
In the United States, the cesarean delivery rate continues to rise. In 2007, approximately 32% of all births occurred by Cesarean delivery, translating to 1.4 million women who underwent this operative procedure. Oklahoma is on par with the national average, with 33.6 % of births occuring by Cesarean delivery (1). Although in 2006 Cesarean delivery was the most commonly performed surgical procedure in the United States, it remains vulnerable to common, as well as rare, complications. Despite continued advances in surgical and aseptic technique, surgical site infections (SSI) continue to be an area of concern for patients, physicians, hospitals, and insurers.
In addition to their negative impact on patient quality of life, surgical site infections (SSI) have been estimated to require an additional three thousand dollars per infection in healthcare expenditure (2). In the surgical patient, it has been estimated that SSI account for 25 to 38% of hospital acquired infections (3-4) and 2-5% of patients undergoing surgery of any type will develop a SSI (5). In cesarean delivery in particular, rates of SSI are between 3 to 15%, depending on the population, definition of SSI, and modifiable risk factors (6). In particular, one factor shown to increase risk of SSI in multiple studies is obesity with odds ratios 1.1-4.79 depending on degree of BMI stratification (6-8). Given its prevalence and cost, SSI represents a postoperative complication with far reaching consequences and making it an area of increasing focus for research.
Recently, negative pressure wound therapy has come to the forefront in demonstrating improved healing and reduced complications in open and closed surgical wounds of various types. A review of the literature illustrates that prophylactic negative pressure wound therapy device effectiveness in reducing SSI has not been widely evaluated in cesarean deliveries. The goal of this study is to evaluate wound infection rates with the use of the Prevena Incision Management System in obese patients undergoing non-emergent cesarean delivery at a tertiary care center. We propose to initiate a randomized clinical trial of the Prevena Incision Management System in a novel population of patients at high risk of surgical site infection. Given the possibility of unexpected challenges, we propose to begin this project with a pilot study in order to help elucidate factors that may need to be including in a larger study in the future. Also, we anticipate that the pilot study will give us a better insight into the rates of wound complications and potential difference between groups in order to better power a larger study.
Rationale for study: Obese patients undergoing Cesarean deliveries have frequent SSIs secondary to modifiable and non-modifiable risk factors. A randomized controlled trial of Prevena Incision Management System, a single use negative pressure therapy unit designed for placement over clean closed surgical incisions, will help reduce rates of surgical site infections and increase the overall quality of life of our patients.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Prevena System placement | – | –Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group). |
| Standard of care postoperative care | – | –Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group). |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- All eligible patients will be approached for consent to participate in the study prior to surgical procedure.
Key inclusion criteria (4 listed)
- Women greater than or equal to 18-years-of-age having a non-emergent Cesarean delivery, primary or repeat procedure, without evidence of active infection at the time of the procedure
Key exclusion criteria (8 listed)
- Males
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Rate of Wound Infections
Time frame: The percent of patients with wound infections will be summarized at the 5-7 day post-operative assessment, the 14-21 day post-operative assessment, and the 6-week follow-up visit. The rate of wound infections will be evaluated at each time point.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2013.
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katherine M Smith, MD principal investigator
University of Oklahoma
Elise Eckhardt, MD principal investigator
University of Oklahoma
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pregnancy, run by University of Oklahoma at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 16 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of Wound Infections (time frame: The percent of patients with wound infections will be summarized at the 5-7 day post-operative assessment, the 14-21 day post-operative assessment, and the 6-week follow-up visit. The rate of wound infections will be evaluated at each time point.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2013.